Browsing Tag
biotechnology
67 posts
How Purple Biotech’s CAPTN-3 platform achieved a tri-specific antibody manufacturing milestone with IM1240
Find out how Purple Biotech’s manufacturing milestone for IM1240 is validating the CAPTN-3 platform and transforming tri-specific antibody development.
Can Swiss Rockets’ new CoolMPS deal with MGI Tech make Europe a genomics powerhouse?
Find out how Swiss Rockets AG’s exclusive license for MGI Tech’s CoolMPS sequencing platform could redefine genomics and precision medicine worldwide.
Can Lilly’s milestone-heavy deal for Adverum reshape how Big Pharma acquires gene therapy platforms?
Lilly’s $12.47-per-share buyout of Adverum Biotechnologies puts milestone CVRs at the center of biotech M&A. But can this deal model truly balance risk and reward?
Novartis makes $12bn bet on RNA medicine with Avidity Biosciences acquisition to expand rare-disease pipeline
Find out why Novartis’s $12 billion Avidity Biosciences deal marks a turning point for big pharma’s RNA-therapy ambitions.
Genenta Science partners with Anemocyte to unlock scalable LVV plasmid DNA supply for global cell and gene therapy developers
Find out how Genenta Science and Anemocyte are scaling off-the-shelf LVV plasmid DNA to revolutionize global gene and cell therapy manufacturing.
Applied DNA Sciences makes bold crypto-biotech crossover with $17m BNB treasury and $58m funding
Find out how Applied DNA Sciences is redefining biotech strategy through a $17 million BNB treasury and $58 million private placement plan.
Minerva Neurosciences gains up to $200m to advance Roluperidone toward FDA approval and U.S. market launch
Minerva Neurosciences secures up to $200 million to fund a new Phase 3 trial of Roluperidone and prepare for a potential U.S. launch. Find out what’s next.
Can Azitra’s ATR-01 live microbe therapy finally fix filaggrin loss in ichthyosis vulgaris?
Find out how Azitra’s ATR-01 microbe therapy could repair the root genetic defect in ichthyosis vulgaris and transform dermatology treatment.
Kiniksa’s KPL-387 earns FDA orphan drug nod, advancing next-gen therapy for recurrent pericarditis
Find out how Kiniksa’s KPL-387 won FDA orphan drug status for pericarditis — and what it means for the company’s expanding rare-disease franchise.
Quoin Pharmaceuticals raises up to $104.5M in private placement to fuel its rare disease pipeline
Find out how Quoin Pharmaceuticals secured up to $104.5 million in a milestone-linked private placement to advance its rare disease therapy QRX003 and strengthen investor confidence.